SI1699421T1 - Laktatne soli kinolinonskih spojin in njihova farmacevtska uporaba - Google Patents

Laktatne soli kinolinonskih spojin in njihova farmacevtska uporaba

Info

Publication number
SI1699421T1
SI1699421T1 SI200432176T SI200432176T SI1699421T1 SI 1699421 T1 SI1699421 T1 SI 1699421T1 SI 200432176 T SI200432176 T SI 200432176T SI 200432176 T SI200432176 T SI 200432176T SI 1699421 T1 SI1699421 T1 SI 1699421T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutical use
lactate salts
quinolinone compounds
quinolinone
compounds
Prior art date
Application number
SI200432176T
Other languages
English (en)
Slovenian (sl)
Inventor
Shaopei Cai
Joyce Chou
Eric Harwood
Timothy D. Machajewski
David Ryckman
Xiao Shang
Shuguang Zhu
Augustus O. Okhamafe
Marc S. Tesconi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority claimed from EP04816941.1A external-priority patent/EP1699421B1/en
Publication of SI1699421T1 publication Critical patent/SI1699421T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200432176T 2003-11-07 2004-11-05 Laktatne soli kinolinonskih spojin in njihova farmacevtska uporaba SI1699421T1 (sl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US51791503P 2003-11-07 2003-11-07
US52642603P 2003-12-02 2003-12-02
US52642503P 2003-12-02 2003-12-02
US54601704P 2004-02-19 2004-02-19
EP04816941.1A EP1699421B1 (en) 2003-11-07 2004-11-05 Lactate salts of quinolinone compounds and their pharmaceutical use
PCT/US2004/036941 WO2005046589A2 (en) 2003-11-07 2004-11-05 Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties

Publications (1)

Publication Number Publication Date
SI1699421T1 true SI1699421T1 (sl) 2014-09-30

Family

ID=37510725

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200432176T SI1699421T1 (sl) 2003-11-07 2004-11-05 Laktatne soli kinolinonskih spojin in njihova farmacevtska uporaba

Country Status (3)

Country Link
CN (3) CN1976706B (zh)
SI (1) SI1699421T1 (zh)
ZA (1) ZA200603598B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2865388C (en) 2012-03-08 2022-01-04 Astellas Pharma Inc. Novel fgfr3 fusion
CN103319403B (zh) * 2013-05-10 2016-03-30 重庆理工大学 一种肿瘤血管新生抑制剂己啉酮及其制备方法和用途
CN104529894B (zh) * 2015-01-15 2017-02-22 成都丽凯手性技术有限公司 一种喹啉酮类衍生物及其制备方法
CN105646449A (zh) * 2016-04-07 2016-06-08 戊言医药科技（上海）有限公司 一种多维替尼的制备方法
CN110016014B (zh) * 2018-01-08 2023-02-17 中国科学院上海药物研究所 Ezh2抑制剂及其制备和抗肿瘤治疗中的应用
AU2019413504A1 (en) * 2018-12-26 2021-06-03 Janssen Pharmaceutica Nv Thienopyridinone compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006711B1 (ru) * 2000-09-11 2006-02-24 Чирон Корпорейшн Хинолиноновые производные в качестве ингибиторов тирозинкиназы

Also Published As

Publication number Publication date
CN101160308B (zh) 2011-05-25
CN1878766A (zh) 2006-12-13
CN1878766B (zh) 2011-08-17
ZA200603598B (en) 2008-04-30
CN101160308A (zh) 2008-04-09
CN1976706B (zh) 2012-01-18
CN1976706A (zh) 2007-06-06

Similar Documents

Publication Publication Date Title
HK1097444A1 (zh) 喹啉酮化合物的乳酸鹽和它們的藥物使用
AP2037A (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
IL176248A0 (en) N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
CY2018005I1 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
IL186435A0 (en) Oral pharmaceutical formulations comprising fenofibric acid and/or its salts
HUE056718T2 (hu) Hatóanyag (delafloxacin) meglumin sója és ennek kristályos formái
EP1838291A4 (en) PHARMACEUTICAL FORMULATIONS AND METHOD OF USE THEREOF
HK1116800A1 (en) Arylvinylazacycloalkane compounds and methods of preparation and use thereof
EP1855531A4 (en) METHOD FOR INCREASING THE ORAL BIOVERABILITY OF A MEDICAMENT AND COMPOSITIONS FROM LESS TOXIC OROTATE SALTS
IL185537A0 (en) 7 - (2 - (4 - (3 - trifluoromethyl - phenyl) - 1, 2, 3, 6 - tetrahydro - pyrid - 1 - yl) ethyl) isoquinoline besylate salt, preparation and therapeutic use thereof
PL1937407T3 (pl) Roztwory bezwodnych soli lantanowców i ich otrzymywanie
SI1699421T1 (sl) Laktatne soli kinolinonskih spojin in njihova farmacevtska uporaba
ZA200606065B (en) Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies
HK1077572A1 (en) Pharmaceutical salts of reboxetine
IL162645A0 (en) solid salts benzazepine compounds and their use inthe preparation of pharmaceuticals compounds
GB0312844D0 (en) Use of compounds in medicine
GB0322194D0 (en) Compounds and their medical uses
ZA200709485B (en) Oral pharmaceutical formulations comprising fenofibric acid and/or its salts
GB0317481D0 (en) Nicotinamide derivatives and a tiotropium salt in combination for the treatment of diseases
GB0317497D0 (en) Nicotinamide derivatives and a tiotropium salt in combination for the treatment of diseases
GB0317515D0 (en) Nicotinamide derivatives and a tiotropium salt in combination for the treatment of diseases
GB0317517D0 (en) Nicotinamide derivatives and a tiotropium salt in combination for the treatment of diseases